Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C

TA200 Hepatitis C - peginterferon alfa and ribavirin: review decision - December 2013 information

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 112 KB)

TA200 Hepatitis C - peginterferon alfa and ribavirin: review proposal - October 2013 information

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - provisional matrix of stakeholders

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - provisional matrix of stakeholders (PDF 100 KB)

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013

TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013 (PDF 534 KB)

200th NICE technology appraisal guidance to help tackle growing hepatitis C problem: press release information

Download PDF version

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination information

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination (PDF 212 KB)

Hepatitis C - peginterferon alfa and ribavirin: comments on the ACD received from the public through the NICE website

Hepatitis C - peginterferon alfa and ribavirin: comments on the ACD received from the public through the NICE website (PDF 13 KB)

Hepatitis C - peginterferon alfa and ribavirin: response to consultee, commentator and public comments on the ACD and comments from website consultation

Hepatitis C - peginterferon alfa and ribavirin: response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 57 KB)

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination - consultee and commentator comments on the ACD

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Department of Health

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Department of Health (PDF 39 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - MSD/Schering Plough

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - MSD/Schering Plough (PDF 10 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - NHS Quality Improvement Scotland

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - NHS Quality Improvement Scotland (PDF 16 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Roche

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Roche (PDF 39 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Nursing

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Nursing (PDF 23 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Pathologists

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Pathologists (PDF 64 KB)

Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Southampton Health Technology Assessment Centre

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation document information

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: evaluation report

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: overview

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: overview (PDF 212 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: assessment report

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: assessment report (PDF 1.9 MB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: consultee and commentator comments on the assessment report

Consultee and commentator comments on the assessment report: Department of Health

Consultee and commentator comments on the assessment report: Department of Health (PDF 40 KB)

Consultee and commentator comments on the assessment report: NHS Quality Improvement Scotland

Consultee and commentator comments on the assessment report: NHS Quality Improvement Scotland (PDF 31 KB)

Consultee and commentator comments on the assessment report: Royal College of Nursing

Consultee and commentator comments on the assessment report: Royal College of Nursing (PDF 44 KB)

Consultee and commentator comments on the assessment report: Royal College of Physicians

Consultee and commentator comments on the assessment report: Royal College of Physicians (PDF 96 KB)

Consultee and commentator comments on the assessment report: Roche

Consultee and commentator comments on the assessment report: Roche (PDF 107 KB)

Consultee and commentator comments on the assessment report: Schering-Plough

Consultee and commentator comments on the assessment report: Schering-Plough (PDF 359 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: non-manufacturer submissions

Non-manufacturer submissions: Hepatitis C Trust

Non-manufacturer submissions: Hepatitis C Trust (PDF 43 KB)

Non-manufacturer submissions: Royal College of Physicians and British Society of Gastroenterology

Non-manufacturer submissions: Royal College of Physicians and British Society of Gastroenterology (PDF 103 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: manufacturer submissions (executive summary only)

Manufacturer submissions (executive summary only): Roche

Manufacturer submissions (executive summary only): Roche (PDF 65 KB)

Manufacturer submissions (executive summary only): Schering-Plough

Manufacturer submissions (executive summary only): Schering-Plough (PDF 66 KB)

Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: expert written personal statements

Expert written personal statements: Dusheikp

Expert written personal statements: Dusheikp (PDF 43 KB)

Expert written personal statements: Gore

Expert written personal statements: Gore (PDF 17 KB)

Expert written personal statements: Jose

Expert written personal statements: Jose (PDF 62 KB)

Expert written personal statements: Thomas

Hepatitis C - peginterferon alfa and ribavirin: assessment report

Hepatitis C - peginterferon alfa and ribavirin: final protocol

Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on provisonal matrix 

Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on the draft scope

Hepatitis C - peginterferon alfa and ribavirin: final scope

Hepatitis C - peginterferon alfa and ribavirin: provisional matrix of consultee and commentators

Hepatitis C - peginterferon alfa and ribavirin: draft scope